Transgene S.a annual stock-based compensation
2020
2021
2022
2023
2024
2025
Transgene S.a Stock-Based Compensation Growth & History (TNG)
Transgene S.a's stock-based compensation was €922,000 for fiscal 2025.
View full Transgene S.a company overviewTransgene S.a annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €922,000 | €354,000 | +62.32% |
| 2024 | 2024-12-31 | €568,000 | €278,000 | +95.86% |
| 2023 | 2023-12-31 | €290,000 | −€2.4M | −89.16% |
| 2022 | 2022-12-31 | €2.7M | −€327,000 | −10.89% |
| 2021 | 2021-12-31 | €3.0M | €1.3M | +72.13% |
| 2020 | 2020-12-31 | €1.7M | — | — |
Transgene S.a stock-based compensation trends
Over the last five fiscal years, Transgene S.a's stock-based compensation decreased from €1.7M to €922,000, a change of −€822,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transgene S.a source filings ↗